NDA 019726 · Tersera
Zoladex
Goserelin Acetate · Implantation
NovelLast checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1989
Dec 29, 1989
Approved uses
5
Original approval plus efficacy supplements
Registered trials
381
126 Phase 3, 47 recruiting
FAERS reports
13,568
12,237 serious, 2,422 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 24, 2026.
ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 )]. 1.2 Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )]. 1.3 Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see Dosage and Administration ( 2.3 ) and Clinical Studies ( 14.3 )]. 1.4 Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see Dosage and Administration ( 2.4 ) and Clinical Studies ( 14.4 )]. 1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal...
Mechanism: ZOLADEX is a synthetic decapeptide analogue of GnRH. ZOLADEX acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelin resulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-induced rat mammary tumor and Dunning R3327 prostate tumor.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 27, 1998 Supplement 24 · Efficacy ReviewLetterLabel
- Apr 9, 1998 Supplement 22 · Efficacy Review
- Jun 27, 1997 Supplement 18 · Efficacy Review
- Feb 2, 1993 Supplement 5 · Efficacy
- Dec 29, 1989 Original approval · Type 1 - New Molecular Entity Other Important Information from FDA
1 products under this application
- ZOLADEX · GOSERELIN ACETATE EQ 3.6MG BASE · IMPLANT, IMPLANTATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Goserelin" as an intervention, any sponsor and status, largest first.
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT03701334 · 5,101 participants · Start Dec 7, 2018 · Primary completion May 29, 2030
Drug: Ribociclib · For: Early Breast Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Jonesboro, Arkansas · 387 sites in all
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
NRG OncologyAcademic, hospital or other
NCT05879926 · 3,960 participants (planned) · Start Oct 18, 2023 · Primary completion Jan 2032
Drug: Ovarian Function Suppression + Aromatase Inhibitor; Adjuvant Chemotherapy + Ovarian Function Suppression · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,276 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002651 · 3,040 participants · Start May 1995 · Primary completion Jun 2013
Drug: bicalutamide; goserelin acetate · For: Prostate Cancer
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 14 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,594
- malignant neoplasm progression1,367
- fatigue925
- metastases to bone706
- neutropenia680
- nausea624
- asthenia540
- hot flush527
- diarrhoea521
- off label use493
- pain492
- arthralgia457
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 218 |
| 2006 | 246 |
| 2007 | 274 |
| 2008 | 296 |
| 2009 | 298 |
| 2010 | 265 |
| 2011 | 385 |
| 2012 | 485 |
| 2013 | 405 |
| 2014 | 446 |
| 2015 | 589 |
| 2016 | 571 |
| 2017 | 485 |
| 2018 | 691 |
| 2019 | 777 |
| 2020 | 902 |
| 2021 | 1,190 |
| 2022 | 1,030 |
| 2023 | 1,255 |
| 2024 | 1,020 |
| 2025 | 836 |
| 2026 | 680 |
Recalls
1 FDA enforcement reports for this application.
Aug 31, 2026 · Class II · Ongoing
Temperature Abuse: Product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zoladex (Goserelin Acetate)
2024 spending
$716K
Beneficiaries
105
466 claims
Per beneficiary
$6,823
$1,527.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $852,389 |
| 2021 | $879,982 |
| 2022 | $849,015 |
| 2023 | $711,421 |
| 2024 | $716,394 |
Part B: Zoladex (Goserelin Acetate) · HCPCS J9202
2024 spending
$10.3M
Beneficiaries
2,048
8,842 claims
Per beneficiary
$5,032
2024 ASP limit $635.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,161,257 |
| 2021 | $10,407,420 |
| 2022 | $10,966,920 |
| 2023 | $10,507,401 |
| 2024 | $10,305,181 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, et al. · Ann Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.
Crown J, Stroyakovskii D, Yardley DA, et al. · ESMO Open 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC, Ro J, André F, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Fasching PA, Stroyakovskiy D, Yardley DA, et al. · JAMA Oncol 2025 · Clinical Trial, Phase III, Multicenter Study
- Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Lu YS, Im SA, Colleoni M, et al. · Clin Cancer Res 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Tersera
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.